Clinical bottom line
Pediatric sudden sensorineural hearing loss (SSNHL) with genetic etiologies represents a distinct and increasingly recognized subset of SSNHL cases that may influence diagnostic and therapeutic strategies. Emerging evidence highlights the role of genetic testing in identifying underlying hereditary causes, which can impact prognosis and guide personalized management. Current data support integrating genetic evaluation alongside standard audiologic and imaging assessments to improve etiologic diagnosis. However, therapeutic approaches remain largely empirical, with corticosteroids as first-line treatment and adjunctive therapies under investigation. Clinicians should consider genetic factors in pediatric SSNHL, but further research is needed to define optimal diagnostic algorithms and targeted treatments.
What the evidence shows
Pediatric SSNHL is a rare but urgent otologic emergency characterized by rapid-onset hearing loss, often unilateral, with diverse etiologies including viral, vascular, autoimmune, and increasingly recognized genetic causes (Hanson et al., 2026). While adult SSNHL has been extensively studied, pediatric cases pose unique diagnostic challenges due to variable presentations and limited patient cooperation (Luu et al., 2023).
Recent reviews emphasize that genetic mutations affecting cochlear function, ion channels, and mitochondrial DNA contribute to pediatric SSNHL pathogenesis in a subset of patients (Hanson et al., 2026). Genetic testing panels targeting known deafness genes can identify pathogenic variants, especially in children with a family history or recurrent episodes. This genetic insight may explain cases previously labeled idiopathic and inform prognosis, as some mutations predict progressive or bilateral hearing loss (Hanson et al., 2026).
Diagnostic workup remains multimodal. High-resolution MRI is recommended to exclude retrocochlear pathology and assess inner ear structures; it can also detect labyrinthine hemorrhage or inflammation that may correlate with genetic susceptibility (Herrera et al., 2024a). Complementary audiometric and vestibular testing remains standard (Rodríguez Izquierdo et al., 2024).
Therapeutically, systemic corticosteroids continue as first-line treatment, with early initiation linked to better outcomes (Lambert et al., 2018). However, pediatric-specific data on steroid efficacy are limited and confounded by heterogeneous etiologies (Dedhia et al., 2016). Adjunctive treatments such as hyperbaric oxygen therapy have shown promise in adult SSNHL but lack robust pediatric evidence (Shaheen et al., 2024). The role of targeted therapies based on genetic findings is currently investigational.
Practice patterns reveal variability in pediatric SSNHL management, with underutilization of genetic testing and inconsistent follow-up protocols (Luu et al., 2023). This gap underscores the need for standardized guidelines incorporating genetic evaluation.
Caveats and uncertainty
The evidence base for genetic contributions to pediatric SSNHL is evolving, with many studies limited by small cohorts and retrospective designs (Hanson et al., 2026). The penetrance and expressivity of identified mutations vary, complicating interpretation of genetic test results. Not all pathogenic variants have clear therapeutic implications, and incidental findings may pose counseling challenges.
Imaging findings may be nonspecific, and the sensitivity of MRI for subtle inner ear abnormalities related to genetic etiologies requires further validation (Herrera et al., 2024a). Treatment efficacy data in genetically defined pediatric SSNHL populations are sparse, and no randomized controlled trials have yet evaluated genotype-guided interventions.
The heterogeneity of SSNHL etiologies means that genetic testing should complement, not replace, thorough clinical and radiologic assessment. Cost-effectiveness and accessibility of comprehensive genetic panels remain practical concerns.
How this may change practice
Incorporating genetic testing into the diagnostic algorithm for pediatric SSNHL could shift practice toward more precise etiologic classification, enabling tailored counseling and surveillance for progressive hearing loss. Early identification of hereditary causes may prompt family screening and inform decisions about cochlear implantation or other rehabilitative strategies.
Clinicians should maintain a high index of suspicion for genetic etiologies in children with SSNHL, especially those with bilateral involvement, recurrent episodes, or a positive family history. Multidisciplinary collaboration with genetics specialists is advisable.
While corticosteroids remain the cornerstone of initial management, awareness of genetic factors may guide future targeted therapies as research advances. Adoption of standardized protocols that integrate genetic, audiologic, and imaging data may improve diagnostic yield and patient outcomes.
Ongoing studies are needed to clarify the prognostic significance of specific mutations and to develop evidence-based treatment pathways incorporating genetic information.